Tag: 9 Meters Biopharma Company


9 Meters Is Initiating Phase II of The Vurolenatide VIBRANT Study for Short Bowel Syndrome

9 Meters Biopharma Company (NASDAQ: NMTR) is a clinical biotech corporation that focuses on the unmet and rare needs in gastroenterology. The company recently announced that they were initiating Phase II of the vurolenatide trial, a proprietary glucagon-like, long-acting peptide-1 agonist in people suffering from short bowel syndrome. 9 Meters’ […]